Perioperative Use of Levosimendan Improves Clinical Outcomes in Patients After Cardiac Surgery: A Systematic Review and Meta-Analysis
| Autor: | Hua Qiang, Zhi-Quan Wang, Xiu Luo, Jian-Hua Huo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Time Factors Heart Diseases medicine.medical_treatment 030204 cardiovascular system & hematology Drug Administration Schedule Perioperative Care Ventricular Function Left law.invention 03 medical and health sciences 0302 clinical medicine 030202 anesthesiology law Risk Factors Medicine Humans Renal replacement therapy Cardiac Surgical Procedures Simendan Pharmacology Mechanical ventilation Ejection fraction business.industry Incidence Acute kidney injury Cardiovascular Agents Stroke Volume Perioperative Levosimendan Acute Kidney Injury Length of Stay medicine.disease Intensive care unit Respiration Artificial Cardiac surgery Renal Replacement Therapy Intensive Care Units Treatment Outcome Anesthesia Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of cardiovascular pharmacology. 72(1) |
| ISSN: | 1533-4023 |
| Popis: | Severe postoperative complications can affect cardiac surgery patients. Levosimendan is a novel calcium sensitizer commonly administered after cardiac surgery. However, the patient benefits are controversial. PubMed, Embase, and the Cochrane library were systematically searched for randomized controlled trials comparing levosimendan with control in adult cardiac surgery patients. Twenty-five studies (3247 patients) were included. Pooled data indicated that levosimendan reduced mortality after cardiac surgery [odds ratio (OR) 0.63, 95% confidence interval (CI): 0.47-0.84, P = 0.001]. However, this reduction was restricted to patients with low ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|